Physician profile
Indu Sharma
NPI 1386793313
$15,252.24
in general payments reported to CMS, 2019-2025
83 companies · $2,436 in 2025
The $2,436 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,292 · 2020: $1,644 · 2021: $2,530 · 2022: $2,445 · 2023: $2,369 · 2024: $1,537 · 2025: $2,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,627 · Education: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,627.44 |
| Education | $713.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,334.10 | 2019-2025 | Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $1,142.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,004.74 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Seagen INC. | $940.35 | 2019-2024 | Padcev, Tukysa, Adcetris |
| Amgen INC. | $896.29 | 2019-2023 | Xgeva, Nplate |
| Incyte Corporation | $795.24 | 2019-2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $708.78 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $686.68 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $678.20 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Celgene Corporation | $551.22 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $529.46 | 2019-2025 | |
| Genzyme Corporation | $386.62 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $340.25 | 2021-2025 | Fotivda |
| Beigene USA, INC. | $306.86 | 2020-2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $303.64 | 2019-2023 | Imbruvica |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indu Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.